KIF20A and pancreatic neoplasm: The foundational work by K Imai et al. was pivotal in identifying KIF20A’s overexpression in pancreatic cancer, setting the stage for subsequent immunotherapy research by demonstrating the ability of specific peptides to induce HLA-A2-restricted CD8+ T-cells targeting KIF20A(+) HLA-A2(+) tumor cells, marking a notable advancement in the field [89].